The economic burden of Medicare-eligible patients by MS type

A forum to discuss Chronic Cerebrospinal Venous Insufficiency and its relationship to Multiple Sclerosis.

The economic burden of Medicare-eligible patients by MS type

Postby Cece » Fri May 06, 2011 10:42 am

Value Health. 2011 Jan;14(1):61-9.
The economic burden of Medicare-eligible patients by multiple sclerosis type.
Gilden DM, Kubisiak J, Zbrozek AS.
SourceJEN Associates, Inc., Cambridge, MA, USA.

OBJECTIVE: Although the global rate of multiple sclerosis (MS) is low, a few studies have documented high costs. Costs are highly variable depending on MS stage. This study was designed to assess the economic burden of Medicare-eligible patients by MS type in the United States using a claims-based classification algorithm to examine cost variation by disease stage.

METHODS: A sample of 2003 to 2006 Medicare patients was selected. Cases were classified as pre-existing progressive MS or pre-existing relapsing-remitting MS (RRMS); the latter were further subdivided into relapsing, remitting, or stable.

RESULTS: The sample had 5044 MS subjects, of whom 34.4% had prevalent progressive MS and 65.6% had prevalent RRMS. There were many chronic, comorbid conditions. The mean all-cause Medicare expenditures (not including self-administered medications) per person-year for MS in 2006 were $23,630 for prevalent progressive patients and $5887 for prevalent RRMS patients. Within the RRMS type, Medicare expenditures per person per month in 2006 were $1418 for relapsing patients, $608 for remitting patients, and $331 for stable patients.

CONCLUSIONS: There are substantial cost advantages to Medicare for keeping RRMS patients in a stable health state and in keeping them from advancing in disability severity. The overall cost advantage would be diminished by the large cost burden of comorbidity, which would likely remain fixed with improved MS therapies.
Family Elder
Posts: 9290
Joined: Mon Jan 04, 2010 4:00 pm


Postby 1eye » Fri May 06, 2011 11:18 am

The advantages of a return to the non-disabled state cannot be too strongly stated, in comparison with warehousing and other measures required to cope with the high costs of disability and the even higher costs of the progression of illness.
This unit of entertainment not brought to you by FREMULON.
Not a doctor.
User avatar
Family Elder
Posts: 3709
Joined: Wed Mar 17, 2010 4:00 pm
Location: Kanata, Ontario, Canada

Postby Donnchadh » Sat May 07, 2011 6:12 am

The cost of my CCSVI procedure cost Medicare less then this study result:
"$23,630 for prevalent progressive patients." And that doesn't consider that the CCSVI procedure might potentially be a one time event, whereas the study figure represents an annual cost to Medicare.

Kitty says, "Take that, you stenosis!"

Got MS?.....Get Liberated!
User avatar
Family Elder
Posts: 526
Joined: Sat Jan 23, 2010 4:00 pm

Postby Cece » Sat May 07, 2011 7:48 am

As an RRMS patient, my insurance definitely paid more than the RRMS figure above ($608) for my venoplasty, not to mention my ultrasound and my earlier consult and Haacke protocol MRV.

If venoplasties end up needing frequent repeating, this will be more costly to insurance companies, particularly for RR patients which make up the bulk of MS patients. If venoplasties are done-in-one and prevent further progression, it will be greatly less expensive.
Family Elder
Posts: 9290
Joined: Mon Jan 04, 2010 4:00 pm

Return to Chronic Cerebrospinal Venous Insufficiency (CCSVI)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service